Evaluation of immunomodulatory agents in classically immunologically “cold” cancers using syngeneic mouse models of breast and ovarian cancer

Evaluation of the immune response following treatment with anti‐CTLA‐4 antibody, radiation therapy or the combination in a murine model of breast cancer

Combined dynamic 18F-FDG PET imaging and DCE prediction of treatment response in an orthotopic model of glioblastoma multiforme

Combination of a glycomimetic antagonist to E-selectin and CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates regulatory T Cell infiltration and accelerates time to complete response in the murine CT26 tumor model

Anti-mCTLA-4 treatment results in early and late immune response effects in a murine model of colorectal carcinoma

A comparative evaluation of immunotherapy responses in murine colon carcinoma

Three ways to help prevent dementia and Alzheimer’s disease

June is here—and in addition to officially kicking off summer, it’s also Alzheimer’s and Brain Awareness Month. While June is used to recognize and support those experiencing cognitive decline, it can also be a month for both young and old to take proactive steps to achieve and maintain optimal brain health.

When preeclampsia doesn’t end after delivery: A mother’s experience with postpartum preeclampsia

Erin Kirk shares her experience with postpartum preeclampsia. Learn about Labcorp's comprehensive preeclampsia screening and early preeclampsia detection.

Cell and Gene Therapy Answers: What to know about companion diagnostics development

A companion diagnostic (CDx) is an in vitro diagnostic providing essential information for the safe and effective use of a corresponding therapeutic product. By identifying patients most likely to benefit from or who are at risk of adverse events from a therapy, CDx can help guide decisions for targeted treatment strategies—which is why many regulatory bodies now recommend incorporating CDx within cell and gene therapy (CGT) programs. However, for many developers, questions remain about when CDx are truly needed, how to choose the right CDx partner and the kind of testing required for CDx assays. To gain clarity on CDx strategy and best practices, we spoke with Devin Craven, associate director of regulatory affairs for Labcorp, and Laura Huning, a scientist for Labcorp’s diagnostic development services.